This study is a double-blind randomized clinical trial conducted with two settings in Africa
and one in Asia, namely Côte d'Ivoire, Pemba (Zanzibar, Tanzania) and Lao PDR. This study
aims at providing evidence on the efficacy and safety of co-administered albendazole and
ivermectin versus albendazole monotherapy (standard of care) against whipworm (T. trichiura)
infections in children and adults (6-60 years).
The efficacy of the treatment and potential extended effects on follow-up prevalence will be
determined 14-21 days, 6 months and 12 months post-treatment by collecting another two stool
samples. The cure rate will be calculated as the percentage of egg-positive subjects at
baseline who become egg-negative after treatment.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Jennifer Keiser
Collaborators:
Centre Suisse de Recherches Scientifiques en Cote d'Ivoire Côte d'Ivoire: Centre Suisse de Recherches Scientifiques en Côte d'Ivoire (CSRS) Lao PDR: National Institute of Public Health (NIOPH) Lao Tropical and Public Health Institute Pemba, Tanzania: Public Health Laboratory Ivo de Carneri Public Health Laboratory of Pemba, Tanzania